Diabetes Mellitus Type 2 At Increased Risk Of Cardiovascular Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for diabetes mellitus type 2 at increased risk of cardiovascular disease. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
6
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Diabetes Mellitus Type 2 At Increased Risk Of Cardiovascular Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Lexicon Pharms Inc 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating diabetes mellitus type 2 at increased risk of cardiovascular disease. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
28
2
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Inpefa
SOTAGLIFLOZIN
 Lexicon Pharms Inc 6 61 — 2028-05-04

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7781577 Inpefa method of use 83 2028-05-04
7781577 Inpefa method of use 83 2028-05-04
8476413 Inpefa method of use 83 2028-05-29
8476413 Inpefa method of use 83 2028-05-29
8217156 Inpefa composition of matter 18 2030-10-07
8217156 Inpefa composition of matter 18 2030-10-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8217156 Inpefa composition of matter 18 2030-10-07
8217156 Inpefa composition of matter 18 2030-10-07
8476413 Inpefa method of use 83 2028-05-29
8476413 Inpefa method of use 83 2028-05-29
7781577 Inpefa method of use 83 2028-05-04
7781577 Inpefa method of use 83 2028-05-04

Related